Lobular Breast Cancer Alliance Executive Director, Laurie Hutcheson, recently interviewed Scientific Advisory Board member Dr. Megan Kruse about her new role at Cleveland Clinic as Director of Breast Medical Oncology and Co-Leader of the Breast Cancer Program.  Announced in January, Dr. Kruse has held several key leadership roles at the Cleveland Clinic previously, including Director of Breast Cancer Clinical Research beginning in 2024 and in 2025, she was promoted to Medical Director of the Taussig Cancer Center Clinical Trials Office.

Her primary area of clinical and translational investigation is the optimization of care for patients with lobular breast cancer. She developed the Comprehensive Lobular Breast Cancer Program at Cleveland Clinic, which includes a dedicated invasive lobular carcinoma (ILC) clinical care pathway, an integrated research program, and a philanthropy fund supporting ILC-focused initiatives.

Laurie and Dr. Kruse discuss her perspective on this new position and what her hope is for the future of lobular breast cancer research and care.